Skip to main content


March 09, 2020
Vascular Disease Management  spoke with Daniel Clair, MD, Chairman of the Department of Surgery for the Palmetto Health-USC Medical Group in Columbia, South Carolina. Dr Clair discussed the impact of new technologies for aortic aneurysm therapy on…
August 28, 2018
Rachel Piechowiak, DO, discusses the implications of a US clinical trial which investigated the use of geniculate artery embolization for decreasing inflammation and pain in osteoarthritis-related knee pain by blocking abnormal blood vessels in the…
July 16, 2018
The results of a pilot study suggest that percutaneous CT-guided cryovagotomy is a safe and feasible procedure that may help patients with mild-to-moderate obesity lose weight. The procedure uses CT guidance and argon gas to freeze the posterior…
May 16, 2018
The recent publication of the landmark ATTRACT trial has offered important data on the treatment of acute deep vein thrombosis (DVT). Anthony Comerota, MD, is one of the authors of the paper, and he joined us to explain the findings of the trial and…
March 16, 2017
VDM spoke with George Adams, MD, MHS, at the 43rd Annual VEITH Symposium regarding the ongoing DANCE and LIMBO trials.
February 10, 2017
An interview with the principal investigator of the ongoing DRASTICO trial, which is comparing drug-eluting stent vs drug-eluting balloon in complex patients.
December 29, 2016
Johannes Lammer, MD, is professor of radiology and interventional radiology at the Medical University of Vienna in Vienna, Austria. Dr. Lammer is principal investigator for the ESPRIT I trial, which evaluated the safety and performance of the ESPRIT…
December 05, 2016
At VEITH Symposium, Dr. Ansel shared new findings from subanalyses as well as 5-year results that show widening benefits from the drug-eluting stent.
November 01, 2016
The FDA recently approved a new, more concentrated format of the high-dose bolus of the GP IIb/IIIa agent tirofiban (premixed, ready to use, at 250 mcg/mL in a 15 mL vial). Craig Walker, MD, answers questions about the use of GP IIb/IIIa agents in…
November 01, 2016
The 1-year results from IN.PACT Global confirm safety and effectiveness of the In.Pact Admiral DCB in femoropopliteal lesions. Michael R. Jaff, DO, answers questions about the results and their implications for peripheral vascular therapy.
July 06, 2016
New technologies are forthcoming in venous disease, and there is a growing interest in venous therapy among operators previously focusing on only arterial disease. Venous disease specialist Seshadri Raju, MD, described the changes that need to occur…
Back to Top